Literature DB >> 8478314

Tissue distribution of dirithromycin: comparison with erythromycin.

E Bergogne-Bérézin1.   

Abstract

In order to ensure effective in-vivo activity, high antibiotic concentrations need to be achieved rapidly at the site of the infection and effective post-dosage concentrations should be maintained. Dirithromycin, a new macrolide antibiotic, is converted in vivo to erythromycylamine, which has antimicrobial activity similar to that of the parent compound and a half-life of 20-50 h which allows for once-daily dosing. Both dirithromycin and erythromycylamine are released slowly from the tissue compartment and the major route of elimination is hepatic/faecal: approximately 10% of an oral dose is absorbed and rapidly leaves the circulation to localize in tissues. Dirithromycin and erythromycylamine achieve lung parenchyma concentrations of 1.58-3.81 mg/kg depending on the number of doses administered. Tissue concentrations are significantly higher than simultaneous serum concentrations. Studies in both healthy and pathological lung tissues have shown that significant antibiotic concentrations remain in the tissue 12 and 24 h post-dose. The presence of an inflammatory exudate, especially the phagocytic component, probably contributes to the increased local concentration of dirithromycin found in pathological tissues. The ability of macrolides to concentrate within phagocytes and alveolar macrophages accounts for the observed high lung tissue concentrations of dirithromycin. Dirithromycin also effectively penetrates bronchial secretions: concentrations of 1.04 mg/L 3 h and 1.3 +/- 1.5 mg/L 12 h after a single 250 mg dose. Following a single dose of 500 mg dirithromycin, bronchial mucosa concentrations of > 1.0 mg/kg were detected at 4-24 h post-dose; after multiple doses, concentrations increased to 1.30 mg/kg at 12 h post-dose. Single and multiple 500 mg doses resulted in mean nasal mucosa concentrations of 0.59 +/- 0.17 and 1.86 +/- 0.54 mg/kg (multiple dose) at 24 and 12 h, respectively. Administration of single oral doses of 500 mg 12 or 24 h before tonsillectomy resulted in 24 h post-dosing tonsillar concentrations of 0.60 +/- 0.55 mg/kg (56% of the 12 h concentrations) while doses of 1000 mg/day for two days, resulted in tonsillar antibiotic concentrations of 1.37 +/- 0.55 mg/kg which were maintained for 24 h after the last dose. Dirithromycin also penetrates prostatic tissue with concentrations of 4.1-6.5 mg/kg achieved 15-17 h after the second of two 500 mg doses. In conclusion, dirithromycin exhibits good tissue distribution within selected tissues, is rapidly distributed and persists in significant concentrations up to 24 h post-dose. These studies suggest that dirithromycin has an extremely large volume of distribution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478314     DOI: 10.1093/jac/31.suppl_c.77

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

4.  Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis.

Authors:  V S Watkins; M Smietana; P M Conforti; G D Sides; W Huck
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.

Authors:  M Müller; O Haag; T Burgdorff; A Georgopoulos; W Weninger; B Jansen; G Stanek; H Pehamberger; E Agneter; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 6.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.